Global regulators are accelerating the path to first-in-human. Operation Trialblazer, EMA's FAST-EU, TGA's CTN scheme, China's NHC 818 Pathway, and the MHRA 14-day route are rewriting approval timelines. AI is compressing the downstream work too — protocol writing, data analysis, and report generation timelines can be expedited.
But speed at the regulatory gate means nothing without the right hospitals behind it. And without quality data from the right patients at those sites, even the fastest AI-driven process is built on weak foundations.
WeClinicalCRO identifies, qualifies, and delivers the sites that make your trial succeed — across every therapeutic area, with deep oncology expertise.
Approvals are faster than ever. Operation Trialblazer, FAST-EU, TGA's CTN scheme, China's NHC 818 Pathway, and the MHRA 14-day route have compressed timelines from years to months.
But accelerated approval does not accelerate recruitment. It does not improve site readiness. It does not solve the single greatest risk in any trial — whether the sites you choose can actually deliver.
A faster regulatory clock means the cost of a wrong site choice has never been higher.
WeClinicalCRO exists to close the execution gap. We match your protocol to hospitals that can actually deliver: the right patient population, the right investigators, the right infrastructure, and the right evidence of prior performance.
Every study is different. Every indication demands a different site profile. We don't recycle a stale database or hand you a list of names. We conduct study-specific, evidence-based site selection — combining real-world site performance data, investigator track records, patient pool analysis, and on-the-ground country expertise.
The result: a shortlist of sites genuinely capable of executing your protocol — not just any protocol.
Site selection is never just site experience and historical performance. We weigh competitive landscape, disease epidemiology, comparative start-up timelines, your development plan, prior KOL relationships, and local regulatory and reimbursement pathways alignment.
Direct, on-the-ground knowledge across every major trial region — we know which sites run trials well, which investigators deliver, and which hospitals have the infrastructure to match their reputation.
Site performance history, enrolment benchmarks, regulatory timelines, KOL networks, and proprietary intelligence combined into a single evaluation framework for your study.
Machine learning surfaces signal from noise — which site profiles historically succeed for which indications, which recruitment curves are realistic, and where risk concentrates.
Global reach. Local insight. Faster decisions.
We support site selection across the full therapeutic spectrum — cardiovascular, immunology, rare disease, CNS, metabolic, and beyond.
Oncology is where we go deepest. Solid tumors, hematological malignancies, early-phase dose escalation, biomarker-driven populations — the most difficult recruitment challenges in clinical research are where our network and expertise matter most.
Broad enough to serve any trial. Specialized enough to lead in the hardest ones.
Daily-updated headlines on artificial intelligence in clinical trials and regulatory developments across the pharmaceutical industry.
Loading latest headlines…
Whether you are running the study yourself or working with a partner CRO, the quality of your site selection determines the quality of your outcome. Let us find yours.